Introduction {#s001}
============

Angiogenesis is the process of new blood vessel formation from the preexisting vasculature. It is well accepted as a biomarker for the growth, invasion, and metastasis of numerous solid tumors.^[@B1]^ Currently, there is a growing demand for novel noninvasive *in vivo* imaging techniques for response assessment and the pretherapeutic stratification of patients receiving antiangiogenic therapies. It has been suggested that angiogenesis-targeted imaging can provide an early diagnosis and aid in treatment planning and the monitoring of antiangiogenic cancer therapies.^[@B4]^

Integrin α~v~β~3~ is a suitable target for both tumor angiogenesis imaging and antiangiogenic therapy because of its high expression on activated endothelial cells and new blood vessels found in tumors and surrounding tissues, while it is absent in most intact normal tissues.^[@B7],[@B8]^ Therefore, integrin α~v~β~3~ is considered an indicator of activated angiogenesis; imaging of integrin α~v~β~3~ overexpression is a promising technique for the assessment of angiogenesis. Labeled synthetic ligands with demonstrated specificity for integrin α~v~β~3~ have proven to be successful agents for *in vivo* imaging of tumor angiogenesis.^[@B4]^ In particular, agents based on the amino acid sequence Arg-Gly-Asp (RGD) have been identified as useful for tumor angiogenesis imaging.^[@B9]^ A significant correlation between the tracer uptake and the level of angiogenesis has been demonstrated in clinical *in vivo* studies of tumor imaging performed using radiolabeled RGD peptides.^[@B12],[@B13]^

IDA-D-\[c(RGDfK)\]~2~ is a newly developed, cyclic synthetic ligand containing the RGD binding site, with a high affinity (IC~50~ = 50 nM) for integrin α~v~β~3~ during angiogenesis.^[@B14]^ Preclinical imaging studies using ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~ (also known as BIK-505) and single-photon emission computed tomography (SPECT) have demonstrated substantial and specific uptake of the radiotracer at the sites of integrin α~v~β~3~ overexpression in tumors^[@B14]^ and high-risk atherosclerotic plaques in discrimination with inflammation.^[@B15]^ Moreover, a recently published human study demonstrated the preliminary clinical efficacy of ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~ SPECT in the visualization and localization of activated angiogenesis in brain and lung tumors.^[@B16]^ In the study, angiogenesis imaging using ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~ SPECT facilitated the visualization of integrin α~v~β~3~ overexpression in both lung and brain tumors, with no laboratory and clinical adverse events, whereas the relationship between the level of active angiogenesis and glucose metabolism (measured with 2-\[^18^F\]fluoro-2-deoxyglucose and positron emission tomography) was different between lung and brain tumors. Thus, ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~ SPECT is a potential tool for the *in vivo* assessment of angiogenesis through the visualization of integrin α~v~β~3~ overexpression in solid tumors.

Human internal radiation dosimetry for a newly developed radiotracer is essential for the risk-benefit assessment of clinical application. In this study, the authors evaluated the whole-body distribution and radiation dosimetry of ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~ in healthy volunteers using serial emission data sets obtained using a dual head gamma camera system.

Materials and Methods {#s002}
=====================

Healthy volunteers {#s003}
------------------

The present study was approved by the Institutional Review Board of the Seoul National University Bundang Hospital (IRB No.: B-1112-069-004). Informed consent was obtained from all of the individual participants. All the procedures performed were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

The participants were recruited through Internet advertisements and a hospital bulletin board. Six healthy participants (male:female = 2:4; mean age ± SD = 68.3 ± 3.2 years \[range, 64--73 years\]; mean body weight ± SD = 56.5 ± 10.7 kg \[range, 47--77 kg\]) voluntarily participated in the study. Participants were age matched with their previous study against brain tumor and lung cancer patients.^[@B16]^ They had no clinically significant medical or neurologic conditions and presented with no clinically significant abnormalities on physical, neurologic, and laboratory examinations.

Preparation of ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~ {#s004}
--------------------------------------------

The precursor IDA-D-\[c(RGDfK)\]~2~ was generously provided by Bio Imaging Korea Co. Ltd. (Seoul, Republic of Korea), which owns the intellectual property rights. Sodium pertechnetate (^99m^Tc) was eluted daily from ^99^Mo/^99m^Tc-generator (Samyoung Unitech, Seoul, Republic of Korea). Structure of ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~ is provided in [Figure 1](#f1){ref-type="fig"}. ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~ was synthesized following the method described in their previous work.^[@B14]^ A solution of \[^99m^Tc(H~2~O)~3~(CO)~3~\]^+^ (370-740 MBq) in saline (200 μL) prepared according to the protocol described by Alberto et al.^[@B17]^ was added to the precursor in water (300 μL). After stirring the reaction mixture at 75°C for 30 min, the obtained ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~ was purified using semipreparative high-performance liquid chromatography (HPLC; Eclipse XDB-C18 column; 5 mm, 9.4 × 250 mm; Agilent Co., Palo Alto, CA). Their current study followed the same gradient conditions. All radiochemical processes, including ^99m^Tc incorporation, HPLC purification, and tC~18~ Sep-Pak cartridge purification, were conducted within 60 ± 5 min. A quality control check, including pH, endotoxin testing, analytic HPLC, and residual solvents measurement by gas chromatography, was performed before human use; a radiochemical purity of 95% was mandatory. Molar radioactivity of ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~; 3.8 Ci/μmol (the injected chemical dose = 63 ng/kg) was obtained after HPLC purification.

![Chemical structure of ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~.](fig-1){#f1}

Data acquisition {#s005}
----------------

Participants were asked to urinate before the injection of ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~. Philips ADAC Forte dual-head gamma camera (Philips Medical Systems, Andover, MA) was used to acquire transmission and serial emission scan data sets. The photopeak was centered at 140 keV in a 20% width energy window using low-energy high-resolution collimators. Whole-body transmission scan was performed for attenuation correction using a Cobalt-57 flood source just before the injection of ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~. After the transmission scan, acquisition of simultaneous anterior and posterior whole-body emission scans was started at 0, 1, 2, 4, 8, and 24 h postinjection of 388.7 ± 29.3 MBq of ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~. The dose administrated was based on data from previous ^99m^Tc-labeled RGD image studies.^[@B16],[@B18]^ The scan speed was 20 cm/min for the whole body for both the transmission and emission scans. The duration of each whole-body scan was about 10.7 min.

The posterior image was mirrored, and the anterior-to-posterior pixel-by-pixel geometric average of the counts was determined. The calibration factor \[(counts/pixel)/(Bq/pixel)\] was obtained to convert counts/pixel into Bq/pixel using whole-body counts and injected doses (MBq). The attenuation was corrected using the transmission scan data and geometrically averaged first emission scan data under an assumption that the subject did not move during the transmission and first emission scans. Attenuation correction factors of the organs were obtained from attenuation corrected and nonattenuation corrected first scan data and were applied to all time-activity curves of the regions of interest (ROIs).

Quantitative analysis and radiation dose estimation {#s006}
---------------------------------------------------

ROIs were manually drawn over the whole-body images at each time point, identifying high uptake organs such as the liver, kidneys, urinary bladder, gallbladder, spleen, brain, and large intestine to obtain the time-activity curves. The radioactivity of ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~ in each organ was expressed as the percentage injected dose (%ID) per organ calculated as the total activity in the organ ROI (Bq)/injected dose (Bq) × 100.

The number of disintegrations per unit activity administered (residence time) was obtained using the ratio of the cumulative activity and injected dose for each subject. The cumulative activity was obtained from the area under the time-activity curve. The area under the curve was calculated as the trapezoid sum of the observed data and the integral of physical decay for the curve tail after the last scan. The remainder of the body, an important input parameter for OLINDA/EXM 1.1 software (Organ Level Internal Dose Assessment Code, Vanderbilt University, Nashville, TN), was also assessed. If excretion of the radiotracer is prevented, the total residence time, which is the summation of the residence times in all of the organs in the body and the remainder of the body, can be calculated using the following simple equation: $$\documentclass{aastex}\usepackage{amsbsy}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{bm}\usepackage{mathrsfs}\usepackage{pifont}\usepackage{stmaryrd}\usepackage{textcomp}\usepackage{portland, xspace}\usepackage{amsmath, amsxtra}\usepackage{upgreek}\pagestyle{empty}\DeclareMathSizes{10}{9}{7}{6}\begin{document}
\begin{align*}{ \rm{Total \;residence \;time}} = {{ \mathop
\smallint \nolimits_0^ \infty {A_0}{e^{ - \lambda t}}dt} \over
{{A_0}}} = {1 \over \lambda }\\= {{{T_{1 / 2}}} \over { \ln 2}}
\approx 1.443 \times {T_{1 / 2}} ,\end{align*}
\end{document}$$

where *A~0~* is the injected dose, *λ* is the decay constant, and *T~1/2~* is the physical half-life of the radioisotope. In this study, the total residence time was about 8.67 h because the half-life of ^99m^Tc was 6.01 h. The excretion of the radiotracer was assessed by the total radiation counts inside of the body contour of the geometrically averaged whole-body images. The residence time in the remainder of the body was obtained from the total residence time, summation of residence times in all of the organs, and excretion from the body.

Finally, the calculated residence times in each organ and the remainder of the body were used as input parameters for the OLINDA/EXM 1.1 software. The OLINDA/EXM 1.1 reports individual organ doses for 24 organs, effective dose (ED), and effective dose equivalent (EDE) using residence time data with reference to adult male and female models. The EDE and ED were calculated as the weighted sum of each individual organ dose. The weighting factors for the EDE and ED were defined from International Commission of Radiation Protection (ICRP) publications 26 (1979) and 60 (1990).

Results {#s007}
=======

No adverse events were observed. [Figure 2](#f2){ref-type="fig"} shows a geometrically averaged whole-body image 0, 1, 2, 4, 8, and 24 h postinjection. After the intravenous injection, ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~ was rapidly taken up by various tissues and organs. High accumulations were observed in the heart, liver, kidneys, and urinary bladder at the initial phase and in the large intestine only at a very late phase. The residence times and cumulative activity percentage in each organ are shown in [Table 1](#T1){ref-type="table"}; high residence times were reported in the liver, large intestine, urinary bladder, and kidneys. ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~ was mainly eliminated through the hepatobiliary system and the renal system. Mean time-activity curves representing organ distribution details of %ID are shown in [Figure 3](#f3){ref-type="fig"}. The radioactivity in the kidneys, liver, spleen, and brain decreased with time. Organs such as the urinary bladder, large intestine, and gallbladder showed initial accumulation and late washout according to the individuals\' natural absorption and excretion cycles. At 24 h postinjection, the radioactivity of ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~ in almost all of organs had diminished completely, except in the large intestine.

![Planar whole-body images showing biodistribution of ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~ at different times after i.v. injection (from *left* to *right*, 0, 1, 2, 4, 8, and 24 h) in a healthy volunteer.](fig-2){#f2}

![Time-activity (%ID) curves for the organs. Data are mean ± SD.](fig-3){#f3}

###### 

[Cumulative Activity Percentages]{.smallcaps} (%[ID]{.smallcaps}) [and Mean Residence Times (h)]{.smallcaps}

  *Organ*                 \%*ID*         *Residence time (* × *100, h)*
  ----------------------- -------------- --------------------------------
  Urinary Bladder         3.78 ± 2.08    0.33 ± 0.18
  Brain                   0.48 ± 0.24    0.04 ± 0.02
  Gallbladder             0.25 ± 0.12    0.02 ± 0.01
  Kidneys                 2.97 ± 0.29    0.26 ± 0.03
  Liver                   6.09 ± 1.83    0.53 ± 0.16
  Spleen                  0.30 ± 0.23    0.03 ± 0.02
  Large intestine         5.40 ± 1.51    0.47 ± 0.13
  Total body              48.24 ± 3.86   5.85 ± 0.41
  Remainder of the body   67.51 ± 4.70   4.18 ± 0.33
  Outside of the body     32.49 ± 4.70   2.82 ± 0.41

Values are mean ± SD.

The radiation dose to each organ and the effective doses (ED and EDE) obtained using OLINDA/EXM software are listed in [Table 2](#T2){ref-type="table"}. As expected, high radiation doses were reported in the upper large intestine (19.28 ± 4.78 μGy/MBq), urinary bladder wall (19.15 ± 6.84 μGy/MBq), kidneys (15.67 ± 0.90 μGy/MBq), liver (9.13 ± 1.71 μGy/MBq), and gallbladder wall (9.09 ± 2.03 μGy/MBq). Whole-body mean EDE and ED were 7.11 ± 0.58 μGy/MBq and 5.08 ± 0.53 μGy/MBq, respectively.

###### 

[Organ Radiation Doses, Effective Doses, and Effective Dose Equivalents]{.smallcaps}

  *Organ*                               *Radiation dose (μGy/MBq)*
  ------------------------------------- ----------------------------
  Adrenals                              4.81 ± 0.43
  Brain                                 1.46 ± 0.33
  Breasts                               2.03 ± 0.26
  Gallbladder wall                      9.09 ± 2.03
  Lower large intestine wall            4.44 ± 0.52
  Small intestine                       6.18 ± 0.78
  Stomach wall                          4.11 ± 0.48
  Upper large intestine wall            19.28 ± 4.78
  Heart wall                            3.56 ± 0.40
  Kidneys                               15.67 ± 0.90
  Liver                                 9.13 ± 1.71
  Lungs                                 3.21 ± 0.42
  Muscle                                2.97 ± 0.29
  Ovaries                               5.56 ± 0.59
  Pancreas                              4.92 ± 0.49
  Red marrow                            3.07 ± 0.27
  Osteogenic cells                      7.77 ± 0.91
  Skin                                  1.83 ± 0.19
  Spleen                                5.10 ± 1.72
  Testes                                2.72 ± 0.42
  Thymus                                2.80 ± 0.37
  Thyroid                               2.43 ± 0.21
  Urinary bladder wall                  19.15 ± 6.84
  Uterus                                5.70 ± 0.77
  Effective dose equivalent (μSv/MBq)   7.11 ± 0.58
  Effective Dose (μSv/MBq)              5.08 ± 0.53

Values are mean ± SD.

Discussion {#s008}
==========

Recently, angiogenesis imaging targeting integrin α~v~β~3~ has gained widespread attention due to its value in tumor diagnostics and therapy. Studies, including ours, assessing the correlation of angiogenic activity in tumors with overexpression of integrin α~v~β~3~ and tumor metabolism using ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~ SPECT and ^18^F-fluorodeoxyglucose (^18^F-FDG) PET, respectively, have reported on the clinical significance of angiogenesis imaging in solid tumor compared to metabolic imaging, compensating for the lack of biological characteristics in metabolic imaging.^[@B13],[@B16],[@B21]^ Although ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~ SPECT images demonstrated higher tumor-to-normal uptake ratios than ^18^F-FDG PET images in glioma patients and have shown its clinical potential, readily available and cost-effective radiotracers for monitoring angiogenesis are yet to be developed.

Radiotracers for angiogenesis imaging have a potentially broad field of application, spanning from cancer to cardiovascular theranostics. Several RGD peptides have been tested in the recent past, demonstrating that the number of RGD moieties, the isotope, and chelator profoundly affect the synthetic process, binding potential, and *in vivo* biodistribution.^[@B22]^ Other research groups have tried to synthesize ^99m^Tc-labeled RGD analogs containing various ^99m^Tc-chelating moieties such as 2-mercaptoacetyl-glycylglycyl (MAG2) and 6-hydrazinonicotinamide (HYNIC).^[@B23],[@B24]^ However, these ^99m^Tc-chelating moieties of the target compound have significant shortcomings, such as a bulky core size, low metabolic stability, and slow clearance from the normal tissue. Therefore, certain RGD analogs have been formulated to include polyethylene glycol (PEG4) or glycine (G3) linkers to increase the integrin α~v~β~3~ binding affinity in a "bivalent" manner and to improve radiotracer excretion kinetics from normal organs.^[@B24]^ IDA-D-\[c(RGDfK)\]~2~ is a newly developed, cyclic synthetic ligand containing the RGD binding site with a high affinity for integrin α~v~β~3~ during angiogenesis.^[@B14]^

SPECT/computed tomography (SPECT/CT) is a hybrid imaging modality that can longitudinally diagnose the target environment in the same subject across different time points noninvasively. RGD analogs that are labeled with radioisotopes suitable for SPECT detector systems, such as ^99m^Tc, can be used as radiotracers for angiogenesis imaging with SPECT/CT. A clear advantage of the ^99m^Tc-labeled SPECT radiotracer is its potential for clinical use as it is readily available and cost-effective compared to PET. ^99m^Tc-labeled IDA-D-\[c(RGDfK)\]~2~ is a newly developed radiotracer for SPECT (or gamma camera) to visualize angiogenic lesions and is a promising agent for cancer imaging.

Human internal radiation dosimetry for newly developed radiotracers is essential for the risk-benefit assessment of clinical applications, which might influence the choice of the radiotracer. Therefore, in the present study, the authors evaluated the radiation dose exposure in humans who underwent a whole-body ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~ gamma camera scan. The results of the present study indicate that this tracer has favorable whole-body pharmacokinetics in terms of its high renal and hepatic extraction, rapid clearance through the kidneys, gallbladder, and GI tract and low doses in the other organs. The kidney exhibited high accumulation, suggesting the possibility to be the dose-limiting organ when targeting integrin α~v~β~3~ for antiangiogenic therapy. Although the high kidney accumulation is probably caused by the increased arginine residues, the kidney uptake is comparable to other radiolabeled multimeric cyclic RGD peptides and other peptides.^[@B24]^ Activity in the liver and kidneys is substantially eliminated 8 h postinjection, with the excretion of the radiotracer through the large intestine and urinary bladder, with some residual activity in the large intestine. The ED and/or EDE values for other SPECT and/or gamma camera radiotracers commonly used clinically are listed in [Table 3](#T3){ref-type="table"}; the ED and EDE values for ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~ are comparable to those of other ^99m^Tc-labeled radiotracers. To their knowledge, their study is the first reported evaluation of the human internal dosimetry of ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~ and represents an advancement in the quest for an ideal SPECT tracer for angiogenesis imaging.

###### 

[The Effective Radiation Doses of]{.smallcaps} ^99[m]{.smallcaps}^[Tc-Labeled Single Photon Emission Computed Tomography Radiotracers]{.smallcaps}

  *Radiotracer*                   *Effective dose (μSv/MBq)*   *Effective dose equivalent (μSv/MBq)*   *Reference*
  ------------------------------- ---------------------------- --------------------------------------- -------------
  ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~   5.08                         7.11                                    Herein
  ^99m^Tc-MDP                     5.70                         N/A                                     ^[@B27]^
  ^99m^Tc-DTPA                    N/A                          8.91                                    ^[@B28]^
  ^99m^Tc-MAG3                    N/A                          10.00                                   ^[@B28]^
  ^99m^Tc-TRODAT-1                10.54                        12.97                                   ^[@B29]^
  ^99m^Tc-MIBI                    11.00                        N/A                                     ^[@B30]^

The present study is limited by its small sample size. Because of the limited number of participants, the authors did not calculate the doses for subject-specific organ volumes. Rather, the authors computed the doses according to the OLINDA/EXM 1.1 reference phantoms. This approach is reasonable for low-dose range radiopharmaceutical compounds typically used in diagnostics, in which patient radioprotection is the main concern, because ED is a metric used for assessing stochastic risk in a population. On the contrary, the use of subject-specific organ masses would be crucial if a therapeutic approach was considered. Another limitation is the quantification of the dual-head gamma camera data. The geometric mean method using simultaneously acquired anterior and posterior images, which the authors adopted here, is certainly useful in activity quantification. However, its accuracy is limited to specific clinical situations. The most fundamental drawback of this method is the fact that it assumes constant attenuation of the photon intensity with the source depth; hence, it does not correct for the contribution of scatter to the counts obtained. This assumption is not valid for the relatively wide window settings used in nuclear medicine. It has been shown that the broad beam attenuation coefficient varies from 0.081 cm^−1^ for a source at 1-cm depth to 0.122 cm^−1^ for a source at 15-cm depth in tissue equivalent material using a 30% window. In addition, the method does not take into consideration the effects of the source thickness and inhomogeneity of the attenuating medium. The source thickness and inhomogeneity effects *in vivo* may be as high as 20% each.^[@B31]^

As mentioned earlier, integrin α~v~β~3~ is a suitable target not only for tumor angiogenesis imaging but also for antiangiogenic therapy. In an aspect of radiotheranostics, the peptide IDA-D-\[c(RGDfK)\]~2~ is possibly transformed into a therapeutic radiopharmaceutical compound when it is labeled with beta-emitting radioisotopes such as rhenium-188 (^188^Re), as previously reported.^[@B14]^ Hence, target distribution and dosimetry studies of beta-emitting radioisotope labeled IDA-D-\[c(RGDfK)\]~2~ must be performed as previously mentioned, to utilize its strength as a radiotheranostic radiopharmaceutical. In specific, pretherapeutic scans with ^99m^Tc-IDA-D\[c\[RGDfK\]~2~ could aid the decision process of ^188^Re-IDA-D\[c\[RGDfK\]~2~ radiation dosage prescription, predicting the possible radiation accumulation to critical nontarget organs such as the kidney.

To conclude, the radiation dosimetry results for ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~ are comparable to the data reported for other ^99m^Tc-labeled radiotracers, and thus, possible diagnostic use of the new radiotracer does not escalate the radiation risk to the patient. This study demonstrates that ^99m^Tc-IDA-D-\[c(RGDfK)\]~2~ is an efficacious and safe radiotracer for imaging integrin α~v~β~3~ expression.
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